Under the terms of the licence agreement, F-star Alpha receives an exclusive licence to FS102, an Fcab™ antibody fragment, which eliminates HER2-positive cancer cells through a novel apoptotic mechanism of action. Furthermore, a genetic predictive biomarker has been identified, which allows selection of patients likely to respond to therapy. FS102 is now progressing to clinical testing in breast, gastric and colorectal cancer.
In addition, F-star Alpha receives a licence for the generation of Fcabs or bispecific antibodies (mAb2™) against up to 22 other oncology and immuno-oncology targets. In return, F-star will receive a combination of milestone payments and tiered royalties.
F-star Alpha is funded through a Series A investment of €9.4m from Atlas Venture, Aescap Venture,
"We are very pleased to announce the creation and funding of F-star Alpha, the first asset-centric vehicle, which exclusively comprises key assets of the F-star family", said
Notes to Editors: About F-star F-star is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab™ antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-star's Modular Antibody Technology™ enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology™, F-star generates bispecific antibodies (mAb2™) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates.
Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture,
Full preclinical data on FS102 is being presented at the
For more information visit www.f-star.com
Keywords for this news article include: Drugs, F-star, Genetics, Oncology, Technology, Biopharmaceuticals, Banking and Finance, Cancer Gene Therapy, Venture Capital Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- GM to Stop Making Autos in Australia
- Selena Gomez, Shakira Among Top Hispanic Searches
- PhD Project Grooms Business Profs
- How Bitcoin and Other Cryptocurrencies Work
- It's Primary Time in Texas
- How to Survive a Subzero Stranding
- Pacific Trade Pact Delay Hinders U.S. Pivot to Asia